NCT07648667

Brief Summary

Perimenopause is when you have symptoms of menopause but your periods have not stopped. Brain-related changes are just one of the many symptoms that occur, and changes to memory and concentration ("brain fog") are frequently reported to be a challenge to those experiencing them. Diet is also understood to play an important role during menopause, however there is still more to learn about the direct impact of nutrition on brain-related symptoms associated with perimenopause. The aim of this research is to identify mental tasks capable of capturing perimenopause-related changes and to better understand how diet might account for differences in mental task performance.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
1mo left

Started Jun 2026

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress50%
Jun 2026Jul 2026

Study Start

First participant enrolled

June 1, 2026

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

June 8, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 15, 2026

Completed
16 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2026

Last Updated

June 15, 2026

Status Verified

June 1, 2026

Enrollment Period

1 month

First QC Date

June 8, 2026

Last Update Submit

June 12, 2026

Conditions

Keywords

PerimenopauseCognitive FunctionBrain FogDietNutritionFood Frequency QuestionaireMenopause Rating Scale

Outcome Measures

Primary Outcomes (19)

  • Numeric working memory task % accuracy

    Cognitive function - working memory task. Measured as a percentage, with a higher score indicating better performance

    Baseline

  • Numeric working memory task reaction time

    Cognitive function - working memory task. Measured as correct reaction time (in milliseconds) with a lower score indicating better performance.

    Baseline

  • 3-back task % accuracy

    Cognitive function - working memory task. Measured as a percentage, with a higher score indicating better performance

    Baseline

  • 3-back task reaction time

    Cognitive function - working memory task. Measured as correct reaction time (in milliseconds) with a lower score indicating better performance.

    Baseline

  • 3-back task number of false alarms

    Cognitive function - working memory task. Measured as number of errors with a lower score indicating better performance.

    Baseline

  • Corsi blocks task score

    Cognitive function - working memory task. Scored as level of difficulty reached (4 upwards), with a higher score indicating better performance

    Baseline

  • Alphabetic working memory task % accuracy

    Cognitive function - working memory task. Measured as a percentage, with a higher score indicating better performance

    Baseline

  • Alphabetic working memory task reaction time

    Cognitive function - working memory task. Measured as correct reaction time (in milliseconds) with a lower score indicating better performance.

    Baseline

  • Word recognition % accuracy

    Cognitive function - episodic memory. Measured as a percentage, with a higher score indicating better performance

    Baseline

  • Word recognition reaction time

    Cognitive function - episodic memory. Measured as correct reaction time (in milliseconds) with a lower score indicating better performance.

    Baseline

  • Picture recognition % accuracy

    Cognitive function - episodic memory. Measured as a percentage, with a higher score indicating better performance

    Baseline

  • Picture recognition reaction time

    Cognitive function - episodic memory. Measured as correct reaction time (in milliseconds) with a lower score indicating better performance.

    Baseline

  • Stroop task % accuracy

    Cognitive function - selective attention and inhibitory control task. Measured as a percentage, with a higher score indicating better performance

    Baseline

  • Stroop task reaction time

    Cognitive function - selective attention and inhibitory control task. Measured as correct reaction time (in milliseconds) with a lower score indicating better performance.

    Baseline

  • Digit vigilance task % accuracy

    Cognitive function - attention task. Measured as a percentage, with a higher score indicating better performance

    Baseline

  • Digit vigilance task reaction time

    Cognitive function - attention task. Measured as correct reaction time (in milliseconds) with a lower score indicating better performance.

    Baseline

  • Digit vigilance number of false alarms

    Cognitive function - attention task. Measured as number of errors with a lower score indicating better performance.

    Baseline

  • Choice reaction time task % accuracy

    Cognitive function - attention task. Measured as a percentage, with a higher score indicating better performance

    Baseline

  • Choice reaction time task reaction time

    Cognitive function - attention task. Measured as correct reaction time (in milliseconds) with a lower score indicating better performance.

    Baseline

Secondary Outcomes (2)

  • Menopause symptom severity

    Past 6 months

  • Brain fog severity

    Past 6 months

Study Arms (2)

Perimenopausal women who report being severely affected by cognition-related/brain fog symptoms

30 perimenopausal women aged 40-55 who report being severely affected by cognition-related/brain fog symptoms

Perimenopausal women who do not report being severely affected by cog-related/brain fog symptoms

30 perimenopausal women aged 40-55 who do not report being severely affected by cognition-related symptoms/brain fog.

Eligibility Criteria

Age40 Years - 55 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Perimenopausal women aged 40-55 years who report being severely affected by cognitive symptoms/brain fog and those who do not report being severely affected.

You may qualify if:

  • Aged 40-55 years
  • Self-assess as healthy
  • Experienced troublesome perimenopause symptoms for at least the past 6 months (as assessed by the Menopause Rating Scale)
  • Not post-menopause (defined as 12 months with no periods)
  • Non-smoker (including vaping)
  • Not lactating or pregnant (or seeking pregnancy)
  • Oral contraception and hormone replacement therapy allowed if taken for at least 3 months prior
  • Cognitive symptoms/brain fog are not required for participation

You may not qualify if:

  • Post-menopause (12 months with no periods)
  • Medically induced perimenopause symptoms
  • Antidepressant/antianxiety medication or other medication likely to affect cognition in the past 6 months
  • Receiving gender-affirming hormone therapy
  • Nutritional supplementation (apart from vitamin D) within the last month (more than 3 consecutive days or 4 total)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

School of Psychology, Northumbria University

Newcastle upon Tyne, Tyne & Wear, NE1 8ST, United Kingdom

Location

MeSH Terms

Conditions

Mental Fatigue

Condition Hierarchy (Ancestors)

FatigueSigns and SymptomsPathological Conditions, Signs and SymptomsBehavioral SymptomsBehavior

Study Officials

  • Fiona Dodd

    Northumbria University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 8, 2026

First Posted

June 15, 2026

Study Start

June 1, 2026

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

July 1, 2026

Last Updated

June 15, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will share

An anonymised dataset will be shared on this platform within the results section. Any information which may identify individual participants will be removed from the dataset before it is shared. Data will be shared in accordance with FAIR (findable, accessible, interoperable, reusable) principles. Participants will consent to the data being shared in this way.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Data will be available 3 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.
Access Criteria
Fully accessible

Locations